Laboratory for molecular neuropharmacology 

Early (1-4 weeks) and late (9 months) changes in brain insulin system, additionally
corticosterone measurements in brain and plasma of STZ-icv rat model

1.1.2010. - 31.12.2010

IGF-I receptor, neurogenesis and chronic intensive physical activity in STZ-icv rat
model (up to 2 months, 3 mg/kg dose)

1.1.2009. - 31.12.2009.

Influence of enriched environment and intensive mental activity on cognitive deficits
and brain insulin system dysfunction in STZ-icv rat model, preliminary
immunohistochemistry of amyloid beta 1-42 in STZ-icv rat model (3, 6 and 9 months, 3
mg/kg dose)

1.1.2008. - 31.12.2008

Therapeutic potential of novel drugs (M30 and HLA20, iron chelators) on prevention of
Biochemical (insulin and insulin receptor, antioxidative capacity) and cognitive changes
in the brain of STZ-icv rat model (1 and 3 month, 3 mg/kg dose)

1.1.2007. - 31.12.2007.

Biochemical (insulin and insulin receptor /IR/, antioxidative capacity) changes in the
brain of STZ-icv rat model (1 and 3 month, 3 mg/kg dose)

1.1.2006. - 31.12.2006.

Biochemical (GSK-3 and protein kinase B) and structural changes in brain (Congo red
staining of amyloid beta) of STZ-icv rat model (1 and 3 month, 3 mg/kg dose)

1.1.2005. - 31.12.2005.

Early (1 month) biochemical (dysfunction of glycogene-syntahse-kinase 3 /GSK-3/)
and behavioural (nociception) alterations in STZ-icv rat model (1 mg/kg dose)

1.1.2004. - 31.12.2004.